The 'gold standard' for the treatment of polycythemia vera (PV) is to date undefined. We performed a retrospective analysis to evaluate the outcome of a cohort of PV patients treated with pipobroman (PB) at a single institution during a period of 20 years (November 1971-October 1991). During this period, a total of 366 adult PV patients were diagnosed according to Polycythemia Vera Study Group (PVSG) criteria. Of these, only 199 (54%) were treated with PB: 92 were males and 107 females, median age was 63.0 years (range 25.2-87.3 years). Major clinical characteristics at onset were as follows: 34 (17%) patients had splenomegaly Ͼ3 cm below costal margin, 70 (35%) had platelets Ͼ600 000/mm 3 , 79 (40%) had white blood cells Ͼ12 000 mm 3 ; 97 (49%) had hypertension, 83 (42%) had minor neurological symptoms (as vertigo, headache, paresthesias), 33 (17%) had pruritus and 27 (13%) had thrombotic features. All patients received PB at the dosage of 1 mg/kg/day until response was achieved (hematocrit value Ͻ50% in males and Ͻ45% in females). Thereafter treatment was given according to toxicity and maintenance of response. All patients were phlebotomized before starting treatment (mean number of phlebotomies performed: three, range 2-4) and 47 of them received PB when hematocrit value was already reduced at response levels: therefore, while all patients are evaluable for acute and long-term toxicity, only 152/199 (76.4%) patients are evaluable for response to PB. During a median time of 2 months, all these 152 patients achieved the response; as maintenance, 128/199 (64.3%) patients were managed with PB alone and 71/199 (35.7%) patients received phlebotomies occasionally. Sixty-one out of 199 (30.6%) patients developed disease-related complications (25 neurological symptoms, 21 thrombotic complications, 12 cardiovascular problems, three hepatic failures). Eleven (5.5%) patients developed acute myelogenous leukemia (AML) after a median time of treatment of 89 months (range 33-188 months), 11 (5.5%) patients developed myelofibrosis (median time from treatment 71 months, range 31-182 months) and in six (3%) patients cancer occurred (median time from treatment 85 months, range 13-118 months). The cumulative risk of leukemia in PV was 2% (95% CI: 0-4%) and 6% (95% CI: 1-11%) at 5 and 10 years respectively; the cumulative risk of myelofibrosis was 2% (95% CI: 1-5%) and 9% (95% CI: 3-15%) at 5 and 10 years, respectively. As of May 1996, 33 (16.6%) patients are lost to follow-up, 40 (20.1%) are dead and 126 (63.3%) are alive with a median overall survival of 191 months. In conclusion, this retrospective analysis confirms the efficacy and safety of PB in PV patients and its low leukemogenic role; prospective studies are needed to evaluate the real impact of PB in the treatment of PV.
Introduction
Polycythemia vera (PV) is a myeloproliferative disorder in which the primary manifestation of the disease is the expan- sion of the red cell mass. Hemostatic complications during the course of the disease affect approximately 30% of patients, while myelofibrotic transformation and evolution in acute leukemia are less frequent in the natural history of the disease. 1, 2 So far a standardized therapeutic approach for the treatment of PV is not yet established, and treatment usually depends on the urgency and the age of the patient.
Although various and different drugs including alkylating agents and radiophosphorus have been found to be effective, the major concern in the management of PV is about the longterm administration of these drugs in younger patients because of their relatively high leukemogenic risk. [1] [2] [3] Pipobroman (PB), a piperazine derivative acting with an alkylating type mechanism, has been shown to be effective in PV patients; [4] [5] [6] however the real impact of this drug on the occurrence of secondary leukemia or a solid tumor is unknown, because of the lack of reports including large series of patients observed over a long-lasting follow-up.
Intending to investigate the influence of PB treatment on the development of acute leukemia in PV patients, we undertook a retrospective analysis on PV patients diagnosed and treated with PB as a single agent between 1971 and 1991 at the Department of Cellular Biotechnologies and Hematology of the University 'La Sapienza' in Rome.
Materials and methods
Between November 1971 and October 1991, 390 PV adult patients were diagnosed at the Hematology Department of the University 'La Sapienza' in Rome. The records of all patients underwent a careful analysis for diagnostic criteria and those cases who failed to meet the Polycythemia Vera Study Group (PVSG) criteria for a PV diagnosis 1 were excluded. As a consequence, 24/390 (6%) patients who did not fit PVSG diagnostic criteria for PV were excluded from the analysis. Moreover, patients managed with different modalities other than PB as single cytoreductive agent were also excluded from the analysis. In particular, we excluded from the evaluation 42 patients managed with phlebotomy, 58 patients with radiophosphorus (P32), eight patients with hydroxyurea (HU), 24 patients with other drugs (busulphan, chlorambucil) and 35 patients with two or more of the above-mentioned treatments.
Therefore, 199 out of 366 patients received pipobroman as single therapeutic agent for 6 months or more and were considered eligible for the analysis. Patients lost to follow-up were censored at the date of their last visit.
The diagnosis of AML was based on French-American-British (FAB) guidelines. 7 The diagnostic criteria of myelofibrosis were as follows: presence of leukoerythroblastic anemia with tear drop erythrocytes, splenomegaly, dry tap bone marrow aspirate associated with (1) histological or ferrokinetic demonstration of extramedullar hematopoiesis; and/or (2) bone marrow biopsy showing an unexplained increase of reticulin fibres with an abnormal proliferation of megakaryocytes.
Treatment
All 199 patients were phlebotomized by local physicians before reaching our Department and starting treatment.
Treatment consisted of oral pipobroman at the dosage of 1 mg/kg/day from day 1 until response (defined as a hematocrit value lower than 50% in males and lower than 45% in females) was achieved.
Thereafter, treatment was given according to toxicity and maintenance of response; occasionally pipobroman was supplemented by phlebotomy to maintain the response. All patients were followed on an outpatient basis at least every 8 weeks.
Among the 199 patients, 47 received pipobroman when the hematocrit level was already below the response value: therefore, while all patients are evaluable for acute and long-term toxicity, only 152/199 (76.4%) patients are fully evaluable for response to PB. Vital status was ascertained for each patient as of 31 December 1995. The analysis was performed in May 1996; the median follow-up for all patients was 92 months (range 14-278 months).
Toxicity
Acute and subacute toxicities were graded according to WHO recommendations. 8 
Statistical methods
Three main outcomes were evaluated by survival analysis: death, progression in acute leukemia and progression in myelofibrosis. The time axis for death was the total observation time in months since diagnosis; the time axis for progression was the time in months from the start of therapy to the first event of progression (ie diagnosis of acute leukemia or myelofibrosis).
Survival distributions for the three outcome measures were generated through the Kaplan-Meier procedure, 9 implemented in the SPSS statistical package. 10 This produced the cumulative risk of the relevant event at 5, 10 and 15 years. The overall mortality rate was given by the total number of events divided by the sum of the observation times across all the subjects.
Univariate differences in survival were tested using the log rank and the Breslow tests, to highlight both later and earlier events respectively. 11 Variables that were statistically significant to either one or the other test were considered for the multivariate analysis, as well as the other baseline characteristics suspected as predictors of survival, based on a priori knowledge.
To estimate the independent effect of each covariate a Cox regression model was performed. 12 The proportional hazards assumption has been checked, for the variables in the final model, testing the significance of the coefficient of the timeby-covariate interaction term, that is defining the variable as a time-dependent covariate and incorporating it into the model.
Results

Patients' characteristics
Clinical characteristics of the 199 patients analyzed are summarized in Table 1 . Males were 92 and females 107, median 
Response to treatment
Pipobroman was effective in all 152 patients fully evaluable for response to PB (median time to response 2 months) and in particular 90% of the entire population achieved the response within 5.6 months.
Of the 152 evaluable patients 52 (34%) had baseline platelets Ͼ600 000/mm 3 ; of these, 35 had normalization of platelet count (platelet Ͻ400 000/mm 3 ) at time of response, 16 patients achieved platelet count Ͻ400 000/mm 3 after an additional median time from evaluation of response of 2 months (range 1-12 months) and in one patient with an initial platelet count of 1 090 000/mm 3 platelets always remained around 500 000/mm 3 . As for the maintenance treatment, 128/199 (64.3%) patients were managed with pipobroman alone; in 71/199 (35.7%) patients, phlebotomies were occasionally added in order to maintain the hematocrit value below 50% in males and 45% in females.
Toxicities, disease-related complications and clinical follow-up Acute toxicity was virtually absent: four (2.5%) patients developed intolerance to the drug, in three cases with cutaneous features and in one case with mild gastro-intestinal symptoms, and one patient had WHO grade 2 gastric hemorrhage. In all cases pipobroman was discontinued: all patients rapidly recovered from the complications and thereafter were successfully treated with lower dosages (50% of the loading dose) of the drug.
Sixty-one out of 199 (30.6%) patients developed diseaserelated complications: 25 patients presented neurological symptoms, in 19 cases related to vasculopathies and in six cases classified as minor symptoms (vertigo, headache or parestesias): 14/19 and 5/6 patients, respectively, have had similar symptoms or have received a diagnosis of hyperten-sion at presentation. Twelve patients had cardiovascular problems during the course of treatment: one patient developed acute myocardial infarction, six patients angina pectoris and five patients had minor symptoms or were diagnosed by instrumental tools; overall, only three out of 12 patients were asymptomatic at time of diagnosis while 9/12 (75%) patients were identified as 'cardiac patients' at onset. Twenty-one patients had thrombotic complications: in particular, 10 had deep venous thrombosis of the lower and upper limbs, seven had superficial lower limb thrombophlebities, two had abdominal infarctions and two had retinal thrombosis. Considering that in four cases thrombosis was found as the main feature at diagnosis, 17 out of 21 patients had de novo thrombosis during treatment. Moreover, 10/17 patients who developed thrombotic complications during treatment had hypertension at diagnosis. Finally, three patients developed hepatic failure.
A total of 11 (5.5%) patients developed acute myelogenous leukemia, without a preceding myelofibrosis phase, after a median time of treatment of 89 months (range 33-188): in one patient AML was preceded by a myelodysplastic phase lasting for 3 months. Eleven (5.5%) patients developed myelofibrosis (median time from start of treatment 71 months, range 31-182): one of these 11 patients progressed to acute leukemia after 13 months. Six (3%) patients developed a solid tumor: median time to cancer diagnosis from start of treatment was 85 months, ranging from 13 to 118 months. The cumulative risk of leukemia in this cohort of PV patients was 2% (95% CI: 0-4%), 4% (95% CI: 1-7%) and 6% (95% CI: 1-11%) at 5, 7 and 10 years, respectively (Figure 1 ). The cumulative risk of myelofibrosis was 2% (95% CI: 1-5%), 4% (95% CI: 1-7%) and 9% (95% CI: 3-15%) at 5, 7 and 10 years, respectively ( Figure 2) .
Causes of death are reported in detail in Table 2 : at the time of analysis, the overall death rate was 20.1%. Acute leukemia was the cause of death in 10 patients, cancer in six and myelofibrosis in five (25, 15 and 13% of total deaths, respectively). Thrombosis was the cause of death in 11 patients (27% of total deaths), thus resulting in a thrombosis-related death rate of 6%. The cumulative risk of death was 7% (95% CI: 3-10%) and 22% (95% CI: 15-30%) at 5 and 10 years, respectively, with an overall mortality rate of 24.5 per 1000 person/year.
As of 31 December 1995, 33 (16.6%) patients are lost to follow-up, 40 (20.1%) patients are dead and 126 (63.3%)
Figure 1
Kaplan-Meier estimate of acute leukemia risk.
patients are alive with a median overall survival of 191 months.
Univariate differences in survival were tested for the following variables: age, sex, hypertension, pruritus, neurological symptoms, thrombotic events, hematocrit value, white blood cells value, platelet value, spleen size, liver size, complications (any) during treatment and phlebotomy during chemotherapy treatment.
White blood cells (WBC) value upper than 20 000/mm 3 and chemotherapy alone (CH) as maintenance treatment were found statistically significant unfavourable prognostic factors (log rank test: P = 0.006 and P = 0.009, respectively). Both variables were confirmed as statistically significant in the ageadjusted analysis performed by Cox regression model ( Figures  3 and 4) , the hazard ratios being 5.2 (95% CI: 1.82-15.04) (P = 0.002) for WBC Ͼ20 000/mm 3 vs WBC Ͻ12 000/mm 3 and 2.9 (95% CI: 1.11-7.74) (P = 0.03) for CH vs CH plus phlebotomy.
Discussion
The definition of the best therapeutic approach to polycythemia vera (PV) is still a controversial issue. Several randomized trials coordinated by the Polycythemia Vera Study Group (PVSG) have clearly demonstrated the efficacy of cytoreductive therapy in preventing the occurrence of arterial and venous thrombosis in PV patients, the main clinical complications of the disease. PVSG Protocol-01 showed a lower incidence of thrombotic events in patients treated with chlorambucil or radiophosphorus (32P) when compared with those managed with phlebotomy. 1 In particular, in phlebotomy-treated patients thrombosis occurred in 34% of the cases, while in 32P-and chlorambucil-treated patients it occurred in 30% and 25% respectively, thus significantly influencing thrombosis-free survival within the first 3 years of the study.
However, the greater efficacy of both myelosuppressive agents was counterbalanced by the increased incidence of acute leukemia and other neoplasms observed in patients randomized in the myelosuppressive arms. At the time of the report, two cases of acute leukemia (1.4%) have been reported among 134 phlebotomy-treated patients, 19 cases of acute leukemia (13.5%) and five cases of non-Hodgkin lymphoma
Figure 2
Kaplan-Meier estimate of myelofibrosis risk. The observed rate of hematologic malignancy in patients treated with either of the two myelosuppressive regimens led PVSG to the conclusion that both agents had to be substituted by a new drug or by a different approach to the disease.
In this framework, in a subsequent randomized study (Protocol-05) aspirin and dypyridamole were randomly added to phlebotomy to prevent phlebotomy-associated thrombotic complications: however, both these drugs failed to protect phlebotomized patients from thrombosis, 13 and the need for an effective, noncarcinogenic, myelosuppressive regimen for PV patients arose.
Over the last 10 years, hydroxyurea (HU), an inhibitor of DNA synthesis by acting as a ribonucleotide reductase inhibitor, has been used because of its presumed lower leukemogenic potential. [14] [15] [16] The results of PVSG Protocol-08 indicated that HU supplemented by occasional phlebotomy was able to decrease the incidence of life-threatening thrombosis when compared with historical phlebotomized patients (13.7 vs 38.1%). In addition, during the first 378 weeks of the study, acute leukemia appeared only in two HU-treated patients (3.9%), leading the authors to conclude that this drug had to be considered the drug of choice, particularly in younger patients previously untreated by myelosuppressive therapy. 16 However, the lack of any leukemogenic potential concerning this drug has not yet been proven and recently a significant occurrence of acute leukemia in PV patients treated with HU has been reported. 17, 18 An update of the PVSG-08 study showed that, after more than 8 years of follow-up, 4/51 (7.8%) patients treated with HU developed acute leukemia, as compared with 2/134 (1.5%, P Ͻ 0.03) historical phlebotomized patients. 17 Weinfeld et al 18 reported a 13% rate of acute leukemia in 30 PV patients treated with HU, including patients previously treated with alkylating agents or 32P; this rate increases when we consider only the previously untreated patients (3/21 or 14%).
Pipobroman, a piperazine derivative acting with a mech- anism of the alkylating type, has been shown to be effective and relatively safe in PV patients: [4] [5] [6] in particular, Bernard et al 4 had a remission rate of 88% and only one case (3%) of transformation to acute leukemia over 33 previously untreated patients in 8.5 years of experience; Najman et al 5 reported a remission rate of 94.4% without any hematologic malignancy in 54 previously untreated over a median follow-up period of 3.6 years and Brusamolino et al 6 obtained a remission rate of 92% with an actuarial risk of acute leukemia of 6% and 9% at 5 and 7 years in a group of 73 previously untreated patients with a median follow-up of 5 years.
Our experience represents the largest series of PV patients treated with PB to date and confirms the efficacy of this drug in inducing a rapid hematologic response and a high response rate as documented by a median time to response of 2 months and a response rate of 90%, respectively.
A maintenance treatment with PB at lower doses than those employed in induction was necessary to avoid wide fluctuations of hematocrit and platelet values: in 64.3% of patients, treatment consisted of PB alone while in the remaining 35.7% phlebotomies were occasionally (mean number of phlebotomies performed in a year: 3, range 2-6) added to PB when platelet and/or WBC low values were a contraindication to increasing the maintenance dose of PB.
The incidence of thrombotic events at diagnosis in our group of patients was 13%, slightly lower than data recently shown in a retrospective analysis on 1213 PV patients by the Gruppo Italiano Studio Policitemia (GISP). 19 During treatment, arterial or venous thrombosis occurred in 21/199 (11%) patients with a thrombotic death rate of 6% confirming the experience of Brusamolino et al. 6 This low thrombotic death rate may explain why survival for patients treated with pipobroman are longer 6 than that achieved with other modalities. 1 The cumulative risk of leukemia (2%, 4% and 6% at 5, 7 and 10 years, respectively) is lower than that observed using other agents such as chlorambucil, 1 32P 1 and carboquone 20 and similar to that observed with HU administration. 17, 18 Obviously the risk of leukemia is significantly lower when phlebotomy is the treatment of choice but this is counterbalanced by an increased incidence of fatal thrombosis in phlebotomized patients, thus resulting in a median survival of 13.9 years, 1 lower than median survival of 15.9 years observed in our group of patients.
The cumulative risk of myelofibrosis in our experience is 2%, 4% and 9% at 5, 7 and 10 years, respectively: these data compare favorably with those reported by Najean et al 21 in the very-long-term course of PV patients managed with 32P or phlebotomy.
In conclusion, this retrospective analysis confirms the effectiveness of PB in treating PV inducing a rapid hematologic response in about 90% of patients, as already demonstrated in small prospective clinical trials: [4] [5] [6] this efficacy is comparable to that of other agents such as 32P 1 and hydroxyurea. [14] [15] [16] The long median overall survival observed could be related to the low incidence of high-risk thrombosis, reflecting a peculiar effect of this drug on thrombopoiesis as suggested by other authors. 6 The incidence of acute leukemia is lower than that observed after 32P or chlorambucil treatment 1 and not higher than that observed after hydroxyurea treatment: 17, 18 therefore, prospective, collaborative and randomized clinical trials are needed to assess the role of these two myelosuppressive drugs on the outcome of PV patients.
